S. Al-Batran

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.

A. Hinke, H. Schmoll, A. Tannapfel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

W. Scheithauer, P. Wirapati, H. Lenz, 2017 .

1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

R. Hofheinz, T. Gaiser, E. Goekkurt, 2021, Annals of Oncology.

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial

J. Trojan, G. Folprecht, M. Schuler, 2017, Zeitschrift für Gastroenterologie.

Pattern of progression and its impact on outcome in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A retrospective multicenter long-term follow-up study.

E. Wardelmann, F. Heidel, T. Fischer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S3-Leitlinie „Magenkarzinom” –

M. Ebert, H. Feußner, P. Malfertheiner, 2011 .

642PTRASTUZUMAB IN COMBINATION WITH DIFFERENT FIRST-LINE CHEMOTHERAPIES FOR TREATMENT OF HER2-POSITIVE METASTATIC GASTRIC CANCER: UPDATED FINDINGS FROM THE GERMAN NON-INTERVENTIONAL STUDY HERMES.

V. Petersen, S. Hegewisch‐Becker, P. Thuss-Patience, 2014, Annals of Oncology.

Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

A. Hinke, H. Schmoll, A. Tannapfel, 2016 .

LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study

P. Bhagia, S. Al-Batran, M. Di Bartolomeo, 2023, Annals of Oncology.

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Z. Wainberg, M. Garrido, S. Al-Batran, 2023, Annals of Oncology.